These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26970585)

  • 1. Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer.
    Wang SR; Malik S; Tan IB; Chan YS; Hoi Q; Ow JL; He CZ; Ching CE; Poh DYS; Seah HM; Cheung KHT; Perumal D; Devasia AG; Pan L; Ang S; Lee SE; Ten R; Chua C; Tan DSW; Qu JZZ; Bylstra YM; Lim L; Lezhava A; Ng PC; Wong CW; Lim T; Tan P
    J Mol Diagn; 2016 May; 18(3):416-424. PubMed ID: 26970585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA.
    Yang X; Chu Y; Zhang R; Han Y; Zhang L; Fu Y; Li D; Peng R; Li D; Ding J; Li Z; Zhao M; Zhang K; Lu T; Yi L; Wu Q; Lin G; Xie J; Liu T; Yang L; Yi X; Li J
    J Mol Diagn; 2017 Jul; 19(4):525-536. PubMed ID: 28502728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
    Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
    Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
    Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
    J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
    Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
    Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a next generation sequencing panel for detection of hotspot cancer mutations in a clinical laboratory.
    Shahsiah R; DeKoning J; Samie S; Latifzadeh SZ; Kashi ZM
    Pathol Res Pract; 2017 Feb; 213(2):98-105. PubMed ID: 28049581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
    Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
    Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.
    Shao D; Lin Y; Liu J; Wan L; Liu Z; Cheng S; Fei L; Deng R; Wang J; Chen X; Liu L; Gu X; Liang W; He P; Wang J; Ye M; He J
    Sci Rep; 2016 Mar; 6():22338. PubMed ID: 26936516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
    Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
    Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
    Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
    Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens.
    Hadd AG; Houghton J; Choudhary A; Sah S; Chen L; Marko AC; Sanford T; Buddavarapu K; Krosting J; Garmire L; Wylie D; Shinde R; Beaudenon S; Alexander EK; Mambo E; Adai AT; Latham GJ
    J Mol Diagn; 2013 Mar; 15(2):234-47. PubMed ID: 23321017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
    Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
    Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
    Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.